Skip to Content
Merck
CN
All Photos(1)

Key Documents

View All Documentation

Y0000520

Nevirapine (anhydrous)

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Nevirapine, 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2′,3′-e][1,4]diazepin-6-one

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H14N4O
CAS Number:
129618-40-2
Molecular Weight:
266.30
MDL number:
MFCD00866928
UNSPSC Code:
41116107
PubChem Substance ID:
329831001
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

nevirapine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC1=CC=NC2=C1NC(C(C=CC=N3)=C3N2C4CC4)=O

InChI

1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)

InChI key

NQDJXKOVJZTUJA-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nevirapine (anhydrous) EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

NNRTI (non-nucleoside reverse transcriptase inhibitor) of HIV-1
Nevirapine is an allosteric, non-nucleoside inhibitor of HIV reverse transcriptase (NNRTI). The Ki for inhibition of wild-type RT by Nevirapine is 200 nM.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0000521

Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001499

Nevirapine hemihydrate, European Pharmacopoeia (EP) Reference Standard

1460703

Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard

1460714

Nevirapine hemihydrate, United States Pharmacopeia (USP) Reference Standard

1460725

Nevirapine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1460736

Nevirapine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1460747

Nevirapine Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1760

Nevirapine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1761

Nevirapine Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1762

Nevirapine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J Ena et al.
HIV medicine, 9(9), 747-756 (2008-07-25)
We performed a meta-analysis to assess the efficacy and safety of switching from protease inhibitor (PI)- to nevirapine (NVP)-based regimens in HIV-infected patients in whom virological suppression had been achieved. Six trials (550 patients) were analysed. The demographics showed that
Prinitha Pillay et al.
PloS one, 8(7), e68995-e68995 (2013-07-31)
There is conflicting evidence and practice regarding the use of the non-nucleoside reverse transcriptase inhibitors (NNRTI) efavirenz (EFV) and nevirapine (NVP) in first-line antiretroviral therapy (ART). We systematically reviewed virological outcomes in HIV-1 infected, treatment-naive patients on regimens containing EFV
Laveeza Bhatti et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 11(6), 369-373 (2012-08-30)
Nevirapine (NVP) was the first nonnucleoside reverse transcriptase inhibitor (NNRTI) approved by the US Food and Drug Administration (FDA) in 1996, for the treatment of HIV infection. Current treatment guidelines include NVP as a component of a recommended alternative NNRTI
J-J Parienti et al.
Medecine et maladies infectieuses, 40(9), 499-505 (2010-05-04)
Taking into account long-term adverse effects of antiretroviral treatment has become a major concern for physicians managing HIV infected patients. More specifically, cardiovascular risk is the fourth cause of death in this population. Nevirapine, when used in antiretroviral naive patients
E V Kazennova
Voprosy virusologii, 54(1), 45-48 (2009-03-04)
The review presents data on the use of a single prophylactic dose of nevirapine at labor given to a mother at the onset of labor in HIV-infected women and neonatal infants within 72 hours after birth in the absence of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service